Hepatic accumulation of S-adenosylmethionine in hamsters with non-alcoholic fatty liver disease associated with metabolic syndrome under selenium and vitamin E deficiency.


Journal

Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731

Informations de publication

Date de publication:
14 02 2019
Historique:
received: 12 05 2017
revised: 27 10 2017
accepted: 09 11 2017
pubmed: 11 11 2017
medline: 26 11 2019
entrez: 11 11 2017
Statut: epublish

Résumé

Progression of non-alcoholic fatty liver disease (NAFLD) in the context of metabolic syndrome (MetS) is only partially explored due to the lack of preclinical models. In order to study the alterations in hepatic metabolism that accompany this condition, we developed a model of MetS accompanied by the onset of steatohepatitis (NASH) by challenging golden hamsters with a high-fat diet low in vitamin E and selenium (HFD), since combined deficiency results in hepatic necroinflammation in rodents. Metabolomics and transcriptomics integrated analyses of livers revealed an unexpected accumulation of hepatic S-Adenosylmethionine (SAM) when compared with healthy livers likely due to diminished methylation reactions and repression of GNMT. SAM plays a key role in the maintenance of cellular homeostasis and cell cycle control. In agreement, analysis of over-represented transcription factors revealed a central role of c-myc and c-Jun pathways accompanied by negative correlations between SAM concentration, MYC expression and AMPK phosphorylation. These findings point to a drift of cell cycle control toward senescence in livers of HFD animals, which could explain the onset of NASH in this model. In contrast, hamsters with NAFLD induced by a conventional high-fat diet did not show SAM accumulation, suggesting a key role of selenium and vitamin E in SAM homeostasis. In conclusion, our results suggest that progression of NAFLD in the context of MetS can take place even in a situation of hepatic SAM excess and that selenium and vitamin E status might be considered in current therapies against NASH based on SAM supplementation.

Identifiants

pubmed: 29122967
pii: CS20171039
doi: 10.1042/CS20171039
doi:

Substances chimiques

Oncogene Protein p55(v-myc) 0
Vitamin E 1406-18-4
S-Adenosylmethionine 7LP2MPO46S
Protein Kinases EC 2.7.-
AMP-Activated Protein Kinase Kinases EC 2.7.11.3
Selenium H6241UJ22B

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

409-423

Informations de copyright

© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Josep Maria Del Bas (J)

Eurecat, Centre Tecnològic de Catalunya, Technological Unit of Nutrition and Health, Reus, Spain.
Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Research Group (GRNS), Reus, Spain.

Benjamín Rodríguez (B)

R&D Department, Quantitative Genomic Medicine Laboratories (qGenomics), Barcelona, Spain.

Francesc Puiggròs (F)

Eurecat, Centre Tecnològic de Catalunya, Technological Unit of Nutrition and Health, Reus, Spain.
Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Research Group (GRNS), Reus, Spain.

Silvia Mariné (S)

Centre for Omic Sciences, Joint Unit Universitat Rovira i Virgili-Eurecat, Centre Tecnològic de Catalunya, Unique Scientific and Technical Infrastructures, Reus, Spain.

Miguel Angel Rodríguez (MA)

Centre for Omic Sciences, Joint Unit Universitat Rovira i Virgili-Eurecat, Centre Tecnològic de Catalunya, Unique Scientific and Technical Infrastructures, Reus, Spain.

David Moriña (D)

Centre for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra (UPF), CIBER Epidemiología y Salud Pública (CIBERESP), 08003 Barcelona, Spain.
Grups de Recerca d'Àfrica i Amèrica Llatines (GRAAL), Unitat de Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.

Lluís Armengol (L)

R&D Department, Quantitative Genomic Medicine Laboratories (qGenomics), Barcelona, Spain.

Antoni Caimari (A)

Eurecat, Centre Tecnològic de Catalunya, Technological Unit of Nutrition and Health, Reus, Spain antoni.caimari@eurecat.org.
Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Research Group (GRNS), Reus, Spain.

Lluís Arola (L)

Eurecat, Centre Tecnològic de Catalunya, Technological Unit of Nutrition and Health, Reus, Spain.
Universitat Rovira i Virgili, Nutrigenomics Research Group; Department of Biochemistry and Biotechnology, Campus Sescelades, Tarragona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH